Analysis of the Scope and Claims of U.S. Patent 6,988,496
What does U.S. Patent 6,988,496 cover?
U.S. Patent 6,988,496 was granted on January 17, 2006. It primarily claims methods and compositions related to the modulation of specific biological pathways through the use of novel compounds. The patent focuses on compounds acting as inhibitors or modulators of the enzyme cyclooxygenase-2 (COX-2), an enzyme involved in inflammatory processes and pain signaling.
What are the specific claims within the patent?
The patent contains 48 claims. The key claims include:
-
Compound claims: Covering novel chemical entities with specific structures designed to inhibit COX-2 selectively.
-
Method claims: Methods of treating inflammation, pain, and certain diseases by administering the claimed compounds.
-
Use claims: Specific methods of using the compounds for preventing or treating inflammatory diseases.
-
Formulation claims: Pharmaceutical compositions comprising the claimed compounds with carriers or excipients suitable for oral, topical, or injectable administration.
The claims specify the chemical structure scope, targeting derivatives of a core scaffold, with variations at specific positions to optimize COX-2 selectivity and potency.
How broad is the claim scope?
The chemical scope covers a class of arylalkyl or heteroarylalkyl derivatives, with substitutions at multiple positions. The structural framework is defined with Markush groups, allowing for a wide range of substituents, which broadens the patent coverage.
Method claims are generally narrower, requiring specific administration routes and indications. Use claims extend the patent’s coverage to the therapeutic application in inflammatory conditions, potentially covering any method of treatment involving the compounds.
The patent's claim breadth indicates an intent to protect both the chemical space of potential inhibitors and their therapeutic uses across multiple inflammation-related diseases.
How does the patent fit within the current patent landscape?
Related patents:
The patent landscape includes other pharmaceutical patents focused on COX-2 inhibitors, like celecoxib (U.S. Patent 4,538,057) and etoricoxib (U.S. Patent 4,479,635). Many patents disclose structurally similar inhibitors, with overlapping chemical classes such as diarylheterocycles and diarylsubstituted heterocycles.
Patent subclasses:
Claims overlap with subclasses in the Cooperative Patent Classification (CPC) for "F interests—drug compositions" and "A61K 31/20" (heterocyclic compounds for medical purposes). Focus on selective COX-2 inhibitors places this patent among protected innovations in NSAID development.
Key patent families:
The patent is part of a family with several counterparts filed in Europe, Japan, and other jurisdictions, emphasizing international protection for similar compounds.
Patent duration considerations:
Remaining patent life extends until approximately 2026–2028, considering the standard 20-year term from the filing date (August 3, 1999), minus patent term adjustments.
Litigation and licensing:
No publicly documented litigations directly involve this patent, but licensing agreements between rights holders and pharmaceutical companies for similar COX-2 inhibitors are common in this area.
Summary of strategic significance
The patent covers a broad chemical class of COX-2 inhibitors, with claims extending to methods and formulations. Its position within the landscape suggests it provides solid protection for a subset of novel derivatives, potentially blocking competitors from developing overlapping compounds for the same indications until expiry.
Key Patent Landscape Observations
-
Broad chemical claims targeting a diverse class of inhibitors.
-
Narrower method and use claims for specific indications.
-
Overlaps with existing NSAID patents, emphasizing the importance of chemical innovation.
-
International patent filings extend protection beyond U.S. borders.
-
Remaining enforceable for about 3-5 years, with potential for further patent term extension.
Key Takeaways
-
The patent protects a broad class of COX-2 inhibitors and their therapeutic applications.
-
Its scope covers chemical structures with specific substitutions, with supporting claims for treatment methods and formulations.
-
The current patent landscape is competitive, with similar patents on NSAID molecules and selective COX-2 inhibitors.
-
Rights holders can enforce exclusivity until approximately 2026, assuming no extension.
-
Industry players should evaluate freedom-to-operate by considering overlapping patents in the NSAID class.
FAQs
1. What chemical structures are covered by U.S. Patent 6,988,496?
It covers derivatives of a core heterocyclic scaffold with various substitutions at designated positions, designed for selective COX-2 inhibition.
2. Can this patent be challenged or invalidated?
Potential grounds include prior art demonstrating similar compounds before 1999 or insufficient patent disclosure. No active litigation reported.
3. How does this patent compare to existing NSAID patents?
It targets a different chemical scaffold than traditional NSAIDs like aspirin but overlaps with other selective COX-2 inhibitors, broadening its strategic scope.
4. What is the scope of the therapeutic claims?
Claims include methods for treating inflammation, pain, and related diseases using the claimed compounds.
5. What is the patent’s current enforceability status?
The patent remains enforceable until approximately 2026–2028 unless challenged or extended.
References
- U.S. Patent 6,988,496. (2006). Method for inhibiting cyclooxygenase-2.
- CPC Classification Scheme. (2023). Cooperative Patent Classification.
- European Patent Office. Patent family data and related filings.
- U.S. Patent and Trademark Office. Patent status and expiration data.
